[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563718":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hyperbaric Oxygen Therapy","EXPERIMENTAL","Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in 1 month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).",[13],"Procedure: Hyperbaric oxygen therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Symptomatic Treatment","NO_INTERVENTION","Participants receive basic symptomatic treatments like antidiabetic drug, antihypertensive drug, and hepatic protector.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","Hyperbaric oxygen therapy","Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).",[9],[26],{"name":27,"affiliation":28,"role":29},"Miaofang Yang, MD","General Hospital of Eastern Theater Command, China","STUDY_DIRECTOR",[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Lu Chen, MS","CONTACT","800-555-5555","86-18690113660","522023350160@smail.nju.edu.cn",{"name":27,"role":33,"phone":18,"phoneExt":18,"email":38},"doctor_yangmf@126.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"General Hospital of Eastern Theater Command","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":49,"coordinates":50},"Point",[51,52],118.77778,32.06167,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":18,"email":36},"Lu Chen","18690113660",{"type":59,"investigatorFullName":56,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","MS","100563718","hyperbaric-oxygen-therapy-for-metabolic-dysfunction-associated-steatotic-liver-diseases-100563718",false,"NCT06619808","Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases","Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial","MASLD","Inclusion Criteria:\n\n* Metabolic dysfunction-associated steatotic liver disease patients\n\nExclusion Criteria:\n\n* Participants are unfit for hyperbaric treatment.\n* Participants with prior oxygen therapy within the last 6 months.\n* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.\n* Participants with severe organ dysfunctions or malignant tumors.\n* Participants have weight loss plan or major operations within the last 6 months.\n* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.\n* Participants are pregnant or lactating.\n* Participants with claustrophobia or that cannot decompress properly.","ALL","18 Years","75 Years",{"count":73,"type":74},150,"ESTIMATED","INTERVENTIONAL",[77],"NA","The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:\n\nDoes HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?\n\nParticipants will:\n\nReceive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.",[80,81,82],"Metabolic Dysfunction-associated Steatotic Liver Disease","Hepatic Steatosis","Non-alcoholic Fatty Liver Diseases",[80,9,82,84],"Oxygen Therapy","2024-09-28",{"date":87,"type":88},"2024-10-01","ACTUAL",{"date":90,"type":88},"2024-07-29",{"date":92,"type":74},"2026-08-31",{"name":5,"class":6},1]